Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION-4
2015-002353-35Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glecaprevir and pibrentasvir in chronic hepatitis C (CHC), sponsored by AbbVie Inc. Primary endpoint: Sustained virologic response at 12 weeks post-treatment. Started Nov 2015; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-002353-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002353-35.